Xilio Therapeutics (XLO) Income from Continuing Operations (2020 - 2026)
Xilio Therapeutics (XLO) reported Income from Continuing Operations of 14131000.0 for Q1 2026, down 1.59% on a YoY basis from 14359135.8 in Q1 2025, and down 19.12% sequentially from 11863000.0 in Q4 2025.
Xilio Therapeutics (XLO) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Xilio Therapeutics (XLO) has 7 years of Income from Continuing Operations data on file, last reported at 14131000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 1.59% year-over-year to 14131000.0; the trailing twelve-month figure through Mar 2026 stood at 42396000.0 (up 26.35% YoY), and the FY2025 full-year result was 167419000.0, up 3.28% from the prior year.
- Income from Continuing Operations retreated to 14131000.0 in Q1 2026, from 11863000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1997000.0 in Q3 2025 to a low of 24825000.0 in Q2 2022.
- A 5-year average of 17023411.76 and a median of 17404000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations retreated 28.13% in 2022 and soared 86.56% in 2025, its largest moves.
- Tracing XLO's Income from Continuing Operations over 5 years: stood at 24421000.0 in 2022, then gained by 21.33% to 19213000.0 in 2023, then increased by 27.6% to 13911000.0 in 2024, then climbed by 14.72% to 11863000.0 in 2025, then fell by 19.12% to 14131000.0 in 2026.
- Business Quant data shows XLO's Income from Continuing Operations at 14131000.0 in Q1 2026, 11863000.0 in Q4 2025, and 1997000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Xilio Therapeutics | 148.60 Mn | -1.70 Mn | - | -14.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.13 Mn |
| Dec 31, 2025 | -11.86 Mn |
| Sep 30, 2025 | -2.00 Mn |
| Jun 30, 2025 | -14.41 Mn |
| Mar 31, 2025 | -13.91 Mn |
| Dec 31, 2024 | -13.91 Mn |
| Sep 30, 2024 | -14.86 Mn |
| Jun 30, 2024 | -14.88 Mn |
| Mar 31, 2024 | -17.80 Mn |
| Dec 31, 2023 | -19.21 Mn |
| Sep 30, 2023 | -17.40 Mn |
| Jun 30, 2023 | -20.19 Mn |
| Mar 31, 2023 | -23.74 Mn |
| Dec 31, 2022 | -24.42 Mn |
| Sep 30, 2022 | -20.43 Mn |
| Jun 30, 2022 | -24.83 Mn |
| Mar 31, 2022 | -21.42 Mn |
| Dec 31, 2021 | -19.66 Mn |
| Sep 30, 2021 | -31.76 Mn |
| Jun 30, 2021 | -23.11 Mn |